gatifloxacin has been researched along with Infections, Pseudomonas in 11 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 7.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 3.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "Besifloxacin-treated eyes had significantly lower CFU recovered as compared with that of gatifloxacin- and moxifloxacin-treated eyes (P < 0." | 1.37 | Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. ( Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sivagurunathan, N | 1 |
| Krishnan, S | 1 |
| Rao, JV | 1 |
| Nagappa, AN | 1 |
| Subrahmanyam, VM | 1 |
| Vanathi, BM | 1 |
| Sanders, ME | 1 |
| Moore, QC | 1 |
| Norcross, EW | 1 |
| Sanfilippo, CM | 1 |
| Hesje, CK | 1 |
| Shafiee, A | 1 |
| Marquart, ME | 1 |
| Karlowsky, JA | 1 |
| Jones, ME | 1 |
| Thornsberry, C | 1 |
| Evangelista, AT | 1 |
| Yee, YC | 1 |
| Sahm, DF | 1 |
| Jensen, H | 1 |
| Zerouala, C | 1 |
| Carrier, M | 1 |
| Short, B | 1 |
| Moshirfar, M | 1 |
| Mirzaian, G | 1 |
| Feiz, V | 1 |
| Kang, PC | 1 |
| Epstein, SP | 1 |
| Bottone, EJ | 1 |
| Asbell, PA | 1 |
| Sirvent, E | 1 |
| Ruiz, M | 1 |
| RodrÃguez, JC | 1 |
| Royo, G | 1 |
| Mah, FS | 1 |
| Romanowski, EG | 1 |
| Kowalski, RP | 1 |
| Yates, KA | 1 |
| Gordon, YJ | 1 |
| Sato, A | 2 |
| Kitazawa, H | 2 |
| Chida, K | 2 |
| Hayakawa, H | 2 |
| Iwata, M | 2 |
| Jones, RN | 1 |
| Beach, ML | 1 |
| Pfaller, MA | 1 |
11 other studies available for gatifloxacin and Infections, Pseudomonas
| Article | Year |
|---|---|
Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cefoperazone; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combi | 2008 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2011 |
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.
Topics: beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Ga | 2005 |
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disea | 2005 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Com | 2006 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacteria | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Dr | 2006 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Model | 2007 |
Study of the effects of AM-1155 in a rat chronic respiratory tract infection model with Pseudomonas aeruginosa.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Fluoroquinolones; Gatifloxacin; Immunoglobulin A; L | 1995 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinol | 1997 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cipro | 2001 |